Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Recurrence 4Ovarian Neoplasms 4Glioblastoma 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Radiation Pneumonitis 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Fallopian Tube Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Rectal Neoplasms 1Patients With Any Advanced Solid Tumors 1Pancreatic Neoplasms 1Ovarian Diseases 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms by Site 1Neoplasms 1Mesothelioma, Malignant 1Melanoma, Cutaneous Malignant 1Lymphangioleiomyomatosis 1Inflammatory Breast Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Esophagogastric Adenocarcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Recurrence × nintedanib × Clear all
NCT03361319 2020-11-24

N3

Royal Marsden NHS Foundation Trust

Phase 1/2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01610869 2019-05-29

METRO-BIBF

University College, London

Phase 2 Completed
117 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Recurrence

NCT02558387 2015-11-20

Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck

Samsung Medical Center

Phase 2 Unknown
20 enrolled

Recurrence

NCT01380782 2014-08-18

BIBF 1120 for Recurrent High-Grade Gliomas

Dana-Farber Cancer Institute

Phase 2 Completed
37 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Recurrence, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡